Target Validation Information
TTD ID	T29143
Target Name	Interleukin-13 (IL13)
Type of Target	Successful
Action against Disease Model	Tralokinumab	Drug Info	BALB/c mice were treated on days 1 and 3 with CAT-354 (intraperitoneal injection), and h uMan IL-13 was injected intratracheally on days 2 and 4. AHR to methacholine, airway eosinophilia in bronchoalveolar lavage fluid, histologic analysis of goblet cell metaplasia and oesophageal eosinophilia were evaluated. H uMan IL-13 induced airway eosinophilia and goblet cell metaplasia in mice in a dose-dependent manner. Moreover, intratracheal dosing with 25 microg of h uMan IL-13 was sufficient to induce AHR, goblet cell metaplasia and oesophageal eosinophilia. Pretreatment withCAT-354 significantly reduced AHR, airway eosinophilia and oesophageal eosinophilia. These results demonstrate that anti-h uMan IL-13 (CAT-354) is a potential therapeutic treatment for allergic airway and oesophageal diseases.	[1]
References
REF 1	Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy. 2005 Aug;35(8):1096-103.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.